RxDoctor Payments Data

Satya Patel, MD

Family Medicine · Sun City, AZNPI 1952571341

Payments from drug & device makers

$1,748in general payments, 2019–2025

Across 57 payments — averaging $30.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$517
  • AstraZeneca$309
  • AbbVie$125
  • GSK$122
  • Aimmune Therapeutics, Inc.$108
  • Amgen$97
  • plus $471 from 14 others

What the payments were for

  • Food & beverage$1,63293%
  • Education$1167%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,748 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$131,542
Medicare patients
358
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$33,728
XareltoRivaroxaban29$33,646
JanuviaSitagliptin Phosphate27$29,465
JardianceEmpagliflozin21$26,866
GlyxambiEmpagliflozin/Linagliptin21$26,702
EliquisApixaban16$14,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,350
PaxlovidNirmatrelvir/Ritonavir13$5,645
Atorvastatin Calcium391$3,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,695
Tamsulosin Hcl168$2,625
Lisinopril371$2,220
Rosuvastatin Calcium116$1,991
Levothyroxine Sodium196$1,725
Omeprazole92$1,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$14$53,56842 claims
Novo NordiskOzempic$517$33,72826 claims
PfizerEliquis, Paxlovid$88$20,23629 claims
GSKTrelegy Ellipta$122$11,35012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,725196 claims
AbbVieSynthroid$125$99619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →